New Zealand markets closed

MRNA Mar 2023 110.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
68.00+2.76 (+4.23%)
At close: 10:36AM EST
Full screen
Previous close65.24
Open68.00
Bid63.10
Ask65.20
Strike110.00
Expiry date2023-03-17
Day's range68.00 - 68.00
Contract rangeN/A
Volume1
Open interest24
  • Motley Fool

    3 No-Brainer Growth Stocks to Buy in 2023

    In last-year's difficult market, growth stocks were among the first to suffer. Why should we be confident about growth stocks? Moderna (NASDAQ: MRNA) went from zero product revenue prior to the pandemic to about $18 billion annually over the past two years.

  • Business Wire

    Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials

    FREMONT, Calif., February 03, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, kn

  • Motley Fool

    Is Moderna Stock a Buy Now?

    The past three years have been fascinating for Moderna (NASDAQ: MRNA) and its shareholders. Moderna's shares are up by an impressive 731% since early 2020, although its coronavirus-related sales will start falling this year. At this point, it's fair to ask if Moderna can march on and continue delivering market-beating returns, or if the company won't be worth an investment in a post-pandemic world.